Jump to main content
Jump to site search
PLANNED MAINTENANCE Close the message box

Scheduled maintenance work on Wednesday 27th March 2019 from 11:00 AM to 1:00 PM (GMT).

During this time our website performance may be temporarily affected. We apologise for any inconvenience this might cause and thank you for your patience.


Issue 3, 2010
Previous Article Next Article

Antivascular and anticancer activity of dihalogenated A-ring analogues of combretastatin A-4

Author affiliations

Abstract

The generally accepted view is that the 3,4,5-trimethoxy-substituted aromatic A-ring of combretastatin A-4 (CA-4) and its analogues should be conserved in order to maintain biological activity through enforcing an active molecular conformation. Contrary to this, we have found that substituting the larger meta-methoxy groups of CA-4 with smaller halogen atoms results in compounds that are equipotent or more potent than CA-4 itself in vitro.

Graphical abstract: Antivascular and anticancer activity of dihalogenated A-ring analogues of combretastatin A-4

Back to tab navigation

Supplementary files

Publication details

The article was received on 30 Jun 2010, accepted on 21 Jul 2010 and first published on 23 Aug 2010


Article type: Concise Article
DOI: 10.1039/C0MD00095G
Citation: Med. Chem. Commun., 2010,1, 202-208

  •   Request permissions

    Antivascular and anticancer activity of dihalogenated A-ring analogues of combretastatin A-4

    T. M. Beale, R. M. Myers, J. W. Shearman, D. S. Charnock-Jones, J. D. Brenton, F. V. Gergely and S. V. Ley, Med. Chem. Commun., 2010, 1, 202
    DOI: 10.1039/C0MD00095G

Search articles by author

Spotlight

Advertisements